Sarah Verhoeff

Chapter 1 General introduction and outline of this thesis 7
Chapter 2 Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT in patients with newly diagnosed metastatic clear cell renal cell carcinoma. 23
Chapter 3 The value of [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to predict watchful waiting duration in patients with metastatic clear cell renal cell carcinoma. 43
Chapter 4 Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy? 67
Chapter 5 [89Zr]Zr-DFO-durvalumab PET/CT before durvalumab treatment in patients with recurrent or metastatic head and neck cancer 81
Chapter 6 [89Zr]Zr-DFO-avelumab PET/CT in early-stage non-small cell lung carcinoma patients to predict neo-adjuvant avelumab treatment response. 111
Chapter 7 Towards a better understanding of immune checkpoint inhibitor in radiolabeled PET-imaging studies. 129
Chapter 8 Summary, general discussion and future perspectives 137
Chapter 9 Nederlandse samenvatting 151
List of publications 158
PhD portfolio 160
Research datamanagement 162
Dankwoord 164
Curriculum vitae 168